Navigation Links
Actelion Announces Positive Study with Bosentan (Tracleer) in,CTEPH

e list of worldwide patient associations and professional health organizations and additional sources of information.

###

References 1. Nick H & Kim S. Assessment of Operability in Chronic Thromboembolic Pulmonary Hypertension. Proc AmThorac Soc 2006; 3: 584-588 2. Dartevelle P et al. Chronic thromboembolic pulmonary hypertension. Eur Respir J 2004; 23:637-648. 3. LJ Rubin et al. Bosentan therapy for pulmonary arterial hypertension. N Engl J Med. 2002; 346: 896-903 4. Tracleer® SPC Actelion Ltd Actelion Ltd. is a biopharmaceutical company with its corporate headquarters in Allschwil/Basel, Switzerland. Actelion's first drug Tracleer®, an orally available dual endothelin receptor antagonist, has been approved as a therapy for pulmonary arterial hypertension. Actelion markets Tracleer® through its own subsidiaries in key markets worldwide, including the United States (based in South San Francisco), the European Union, Japan, Canada, Australia and Switzerland. At the end of September 2006, Tracleer® was commercially available in 35 countries worldwide. Actelion, founded in late 1997, is a leading player in innovative science related to the endothelium - the single layer of cells separating every blood vessel from the blood stream. Actelion's over 1,200 employees focus on the discovery, development and marketing of innovative drugs for significant unmet medical needs. Actelion shares are traded on the SWX Swiss Exchange (ticker symbol: ATLN). For further information please contact: Actelion Ltd, Gewerbestrasse 16, CH-4123 Allschwil Investor Contact Roland Haefeli +41 61 565 64 58 +1 650 624 6936 Media Contact Peter Engel +41 61 565 66 28 +1 650 624 6996 http://www.actelion.com Conference Call Actelion will host an Investor Conference Call and discussion/Q&A on Monday, 5 March 2007, 07.45 CET / 01.45 AM EST / 06.45 GMT Dial: +41 (0)91 610 56 00 (Europe) +1 (1) 866 291 4166 (U.S.
'"/>




Page: 1 2 3 4 5 6

Related medicine technology :

1. Antisoma Announces Further Data From ASA404 Ovarian Cancer Trial
2. Neose Announces Presentation of Positive Preclinical Data on GlycoPEGylated Factor VIIa at the XXI Congress of the International Society on Thrombosis and Haemostasis
3. Biofrontera AG Announces Clinical Study Confirms Excellent Efficacy of BF-200 ALA In Actinic Keratosis
4. YM BioSciences Announces Secondary Efficacy and Safety Findings in Randomized Phase IIB Aerolef Trial
5. BioSante Pharmaceuticals Announces New Findings for Potential Bird Flu Vaccine
6. Portola Pharmaceuticals Announces Positive Data from a Phase II Study of its Factor Xa Inhibitor at the XXI Congress of the International Society on Thrombosis and Haemostasis
7. Manhattan Pharmaceuticals Announces Results of Phase 2a Studies for Oral Oleoyl-estrone
8. AVI BioPharma Partner Cook Medical Announces Completion of Patient Enrollment for APPRAISAL Phase II Clinical Trial for Treatment of Cardiovascular Disease
9. Protox Announces Positive Clinical Data from Prostate Cancer Study
10. Inspire Announces Webcast of Presentation at C.E. Unterberg, Towbin Emerging Growth Opportunities Conference
11. NexMed Announces Completion of Patient Enrollment in Two Pivotal Phase 3 Studies for Anti-Fungal Product
Post Your Comments:
*Name:
*Comment:
*Email:
TAG: Actelion Announces Positive Study with Bosentan Tracleer CTEPH
(Date:1/15/2014)... , Jan. 15, 2014 ... research report is available in its ... Markets and Technologies for Advanced Drug ... of Administration ...
(Date:1/15/2014)... 15, 2014  A novel wearable injector slightly larger than an ... patients to self-inject prescription drugs in the large doses required ... diseases, autoimmune deficiencies, and genetic disorders.  An ... by 2018, according to analysts.   Many of these drugs will ...
(Date:1/14/2014)... Texas , Jan. 14, 2014  Luminex Corporation (Nasdaq: ... results for the fourth quarter of 2013 on Monday, February ... for release after the close of trading. ... conference call to discuss the operating highlights and financial results ...
Breaking Medicine Technology:Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 2Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 3Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 4Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 5Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 6Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 7Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 8Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 9Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 10Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 11Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 12Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 13Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 14Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 15Global Markets and Technologies for Advanced Drug Delivery Systems -- Focus on Routes of Administration 16Enable Injections Presents A New Class of Injectors for Drug Delivery at PEPTalk, Drug Delivery Partnership Meetings 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 2Luminex Corporation Fourth Quarter Earnings Release Scheduled for February 3, 2014 3
(Date:4/23/2014)... endogenous neural precursor cells cannot alone compensate for ... perspective of neural plasticity, Dr. Yun Xiang and ... the effects of functional electrical stimulation treatment on ... basic fibroblast growth factor and epidermal growth factor ... The researchers found that functional electrical stimulation can ...
(Date:4/22/2014)... industry leaders visited the New Jersey Institute of ... S. Bloom for the launch of the New ... provides a new model for business innovation through ... assets and investment. U.S. Senator Cory Booker, Panasonic ... Taylor, New Jersey Lieutenant Governor Kim Guadagno, New ...
(Date:4/22/2014)... Health clinics that can provide primary care for ... both hospitals and insurance companies while improving patient ... hospital admissions suggests that health clinics that avoid ... save money by lowering hospital admission rates and ... of economics, Penn State Altoona. , The ...
(Date:4/22/2014)... among women using a newer method of planned sterilization ... over a 10-year period than using the more commonly ... University and UC Davis has found. , Published ... the study found the higher risk of pregnancy with ... Essure. , "This study provides essential information for ...
(Date:4/22/2014)... mice and rabbits, Johns Hopkins scientists have found a ... successfully preventing the development of atherosclerosis, the main cause ... of death among humans. The condition develops when fat ... stiff, narrowed and hardened, greatly reducing their ability to ... brain. , In a series of experiments, described April ...
Breaking Medicine News(10 mins):Health News:Government and industry leaders herald launch of NJIT's New Jersey Innovation Institute 2Health News:Clinics not bogged down by red tape can ease health cost burdens 2Health News:Risk of pregnancy greater with newer method of female sterilization 2Health News:Risk of pregnancy greater with newer method of female sterilization 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 2Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 3Health News:Scientists alter fat metabolism in animals to prevent most common type of heart disease 4
... X-rays allowing, dentists to remineralize affected teeth. ... 3 /PRNewswire/ - Quantum Dental Technologies, a Canadian,diagnostic ... monitors the early onset of tooth decay without ... of invasive and painful procedures,and encourages better oral ...
... climate change places 1.7,billion people - 25% of ... warns,anti-poverty agency ActionAid., WASHINGTON, July 2 ... ActionAid launches a new report, "Cereal,Offenders: How the ... and What,They Can Do to Stop It." Read ...
... 2 Regarding the completely fabricated,item about GO3 ... July 14, 2008,edition of Star magazine, none of ... were contacted by the magazine prior to publication., ... reviewing its legal options and will vigorously pursue ...
... Jr,Washington Wizards Guard and Washington, DC native, will ... July 29 featuring bowling at Lucky Strike in,Chinatown. ... support the,cause, including Brendan Haywood and DeShawn Stevenson, ... Vince Carter, Kevin Durant, and,Chris Bosh. Additionally, Craig ...
... individual patients, study says , , WEDNESDAY, July 2 (HealthDay News) ... cells in the blood of lung cancer patients may make ... the genetic "signature" of particular tumors but to monitor changes ... think this is key to personalized medicine," said Dr. Daniel ...
... sports medicine specialist, John Albright, MD, will join three other physicians ... of Fame inductee. , ... Orlando, Florida (PRWEB) July ... MD, will join three other physicians as a 2008 American ...
Cached Medicine News:Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 2Health News:Breakthrough Technology That Will Revolutionize the Treatment of Tooth Decay 3Health News:ActionAid Challenges G8 on Response to Food Crisis 2Health News:GO3 Statement Regarding Erroneous Coverage in Star Magazine 2Health News:Washington Wizards Guard Roger Mason Jr. to Host Bowling at Lucky Strike to Benefit National Kidney Foundation of the National Capital Area 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 2Health News:Circulating Tumor Cells Reveal Insights Into Lung Cancers 3Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 2Health News:Renowned Iowa Orthopaedic Surgeon, John Albright, MD, Inducted into Sports Medicine Hall of Fame 3
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... is a national reference laboratory and a ... development. ARUP offers an extensive test menu ... in clinical and anatomic pathology. Owned by ... include more than half of the nation's ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
... Laboratories is a national reference laboratory and ... and development. ARUP offers an extensive test ... tests in clinical and anatomic pathology. Owned ... clients include more than half of the ...
Medicine Products: